Sumant Kulkarni

Stock Analyst at Canaccord Genuity

(2.23)
# 2,815
Out of 5,040 analysts
114
Total ratings
38.24%
Success rate
-0.42%
Average return

Stocks Rated by Sumant Kulkarni

Atai Life Sciences
Oct 22, 2025
Maintains: Buy
Price Target: $11$14
Current: $5.55
Upside: +152.25%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.02
Upside: +741.58%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83$48
Current: $8.15
Upside: +489.32%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.24
Upside: +140.38%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21$27
Current: $7.08
Upside: +281.36%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73$70
Current: $6.00
Upside: +1,066.67%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158$160
Current: $143.67
Upside: +11.37%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265$220
Current: $150.08
Upside: +46.59%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23$25
Current: $10.68
Upside: +134.08%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14$12
Current: $4.55
Upside: +163.74%
Maintains: Buy
Price Target: $112$80
Current: $2.26
Upside: +3,439.82%
Maintains: Buy
Price Target: $31$28
Current: $13.27
Upside: +111.00%
Maintains: Buy
Price Target: $16$14
Current: $12.47
Upside: +12.27%
Maintains: Buy
Price Target: $21$20
Current: $31.69
Upside: -36.89%
Maintains: Buy
Price Target: $40$33
Current: $21.73
Upside: +51.86%
Maintains: Buy
Price Target: $101$150
Current: $16.30
Upside: +820.25%
Upgrades: Buy
Price Target: n/a
Current: $19.02
Upside: -